In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.
about
Current developments in adenovirus-based cancer gene therapyIn Vivo Noninvasive Imaging for Gene TherapyGene Therapy Applications to Cancer TreatmentPeptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerA phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancerPhase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.Molecular imaging of gene expression and protein function in vivo with PET and SPECT.Cancer gene therapy.Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects.Tissue-specific promoters for cancer gene therapy.Gene expression imaging with radiolabeled peptides.Adenoviruses for treatment of cancer.A heparan sulfate-targeted conditionally replicative adenovirus, Ad5.pk7-Delta24, for the treatment of advanced breast cancer.Gene expression and gene therapy imaging.Gene therapy of gynaecological diseases.Targeting adenoviral vectors for enhanced gene therapy of uterine leiomyomasTargeted Adenoviral Vector Demonstrates Enhanced Efficacy for In Vivo Gene Therapy of Uterine Leiomyoma.Extended release of adenovirus from silica implants in vitro and in vivo.Novel adenoviral gene delivery system targeted against head and neck cancer.Systemic efficacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer.Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.A three-dimensional assay for measurement of viral-induced oncolysis.An adenoviral vector containing an arg-gly-asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression.Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy.Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.Evaluation of a selectively oncolytic adenovirus for local and systemic treatment of cervical cancer.Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies.Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer.
P2860
Q24683229-DF5D6AA3-B47D-4D7D-BC58-C4A2BA25E6BBQ24790997-F980C16E-C570-427A-A59B-0C56AED875D4Q24792808-9A1733C1-DFBC-4193-BF5E-87C282C014CFQ33584756-6124D7C2-4F06-4648-A2A6-86F24B443D27Q33786353-FA115D80-8A66-410E-9BC8-DC6672D1B388Q33932032-5B072DC9-4410-4A0C-BD9F-E8754D2E16A8Q34313234-9D8FF968-F442-4552-BC0B-C9C7E2ECE47FQ34918519-B01BA87F-0C21-4C05-A1F7-AF6EC1EA8D31Q35081097-61DAFB92-7D68-4D56-AD7F-9CC1BBF42553Q35623922-932C48DC-F24A-4C57-84A7-BC556DCF77ACQ35779378-5C4D35C6-8DC5-4B4E-A47E-8C70D6F803F2Q35883797-E55C31D5-6D8F-4DC7-9240-8618506B1BFBQ36132288-058649E2-50BF-4DE7-A98B-F89223BFC9DAQ36158701-64068015-B4DC-4030-8F6A-E543F9EDD262Q36591329-13F3557C-8213-44B6-BE0A-2F0552FF8256Q36922247-D8B09D86-5E0B-4735-AC3A-E2112A084A71Q37109089-DAD5059D-BFDF-4352-9DE4-7E866DEE647EQ38793621-119029C7-2FFF-4E7D-B4E9-EC7F69B510F5Q39946262-80595596-EC54-4A34-93BF-69AC6199E5CEQ40028297-32B3F5D2-3FA0-4AD1-B3DE-A6339F109639Q40168283-4D6F9B70-A3BC-4A5D-B3A6-FA64E7CCB4C2Q40553784-D5419DE1-2CEA-45CE-9139-6253E72C5885Q41813055-85CE1E22-3C1A-4750-B0B6-1B7B9D5ADCA3Q44495836-76CCAEC7-C1F8-4B8A-9485-603F792734CEQ44785625-262D7D30-3523-4FFA-95AE-214C42E1AE0EQ45866775-BD07C23E-CEA2-4C9B-992D-38FEDDAC3D09Q45876078-94A32262-7477-4FE0-873D-89172606C067Q45876668-20753F73-9B92-4FD7-A60D-8C8C6E70CDE8Q45878940-BD82792A-6C70-4164-9542-C3F291EC3339Q50091640-7C93C538-F2C8-474B-BCD7-E7DDFF637E99
P2860
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@en
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@nl
type
label
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@en
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@nl
prefLabel
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@en
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@nl
P2093
P356
P1476
In vivo molecular chemotherapy ...... fectivity-enhanced adenovirus.
@en
P2093
Buck E Rogers
Kurt R Zinn
Mack N Barnes
Renee A Desmond
Ronald D Alvarez
Tandra R Chaudhuri
P304
P356
10.1093/JNCI/94.10.741
P407
P577
2002-05-01T00:00:00Z